Compare MBINM & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MBINM | IMNM |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.5B |
| IPO Year | 2017 | 2020 |
| Metric | MBINM | IMNM |
|---|---|---|
| Price | $25.68 | $26.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | 5.5K | ★ 956.7K |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ 2.73 | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,127.34 |
| P/E Ratio | $9.41 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $24.00 | $8.93 |
| 52 Week High | $25.96 | $30.06 |
| Indicator | MBINM | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 56.62 | 47.75 |
| Support Level | $25.46 | $19.28 |
| Resistance Level | $25.71 | $27.14 |
| Average True Range (ATR) | 0.09 | 1.10 |
| MACD | 0.00 | -0.41 |
| Stochastic Oscillator | 69.70 | 9.58 |
Merchants Bancorp is a United States-based bank holding company operating multiple lines of business focused on FHA multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. Its segments include Multi-family Mortgage Banking, which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing, which offers mortgage warehouse financing, commercial loans and deposit services; and the Banking segment, which generates maximum revenue and provides portfolio lending for multi-family and healthcare facility loans, residential mortgage banking, agricultural lending, SBA lending and community banking.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.